Drug Profile
Zinostatin
Alternative Names: Neocarzinostatin; NSC 157365; NSC 69856Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Unknown
- Developer Kayaku
- Class Antineoplastics; Cytostatic antibiotics; Enediynes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Bladder cancer; Leukaemia; Pancreatic cancer
- No development reported Haematological malignancies
Most Recent Events
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 10 Apr 2003 No development reported - Preclinical for Haematological malignancies (myeloablation) in USA (unspecified route)
- 02 Sep 1999 A clinical study in patients with liver cancer has been added to the therapeutic trials and adverse events section